Huntington's is a dreadful neurodegenerative disease that is mostly inherited and presently incurable. However, several promising new drugs are going through clinical trials, which could drastically improve the quality of life for patients.
One company at the forefront of this medical innovation is IXICO (IXI) , the world’s #1 player for analysing brain scans of Huntington's patients. Indeed, their AI-powered digital imaging platform remains the industry's gold standard for helping biopharma groups develop novel treatments.
Moreover, as further evidence of the quality of its IPR-rich medical services, IXICO said today that in a major scientific breakthrough alongside the Huntington's Disease Imaging Harmonisation consortium, it had scanned >6,000 MRI datasets using its proprietary deep learning algorithms, in order to far more precisely measure changes in brain volume, biomarkers and structures in minute detail. Thus enabling greater insights into the diagnosis, severity, treatment and progression of the disease - especially useful information for patient stratification and the overall optimisation of clinical trials.
CSO Robin Wolz commenting: "[Our work] provides an evidence based biomarker-based framework for the biological definition of HD. The relevant brain volume measurements in a highly accurate and automated tool - allows reliable and robust implementation of HD clinical trials. With this major milestone, we will focus with our partners to put those measures into clinical trial use and build further evidence towards the use of brain volumetric measures."
In terms of valuation, IXICO's shares at 11.75p trade on a modest 1.3x EV/sales, which looks far too cheap for such a science-rich 'picks and shovels' play on the treatment of all things neurodegenerative disease. In comparison, house broker Cavendish has a 24p target price.
Follow News & Updates from IXICO: